Feb 25th 2013 - Edison Investment Research today published a report on Synta Pharmaceuticals entitled "GALAXY-2 Poised To Start". In summary, the report says:
Synta’s investment case now effectively rests on the success of ganetespib in its two target registration indications of non-small cell lung cancer (NSCLC) and metastatic breast cancer (mBC). Following a $60m fund-raising last year, Synta is poised to embark on the c 500 patient GALAXY-2 Phase III study of ganetespib in second-line NSCLC. This will run in parallel with its CHIARA Phase II study in ALK+ NSCLC, while a separate Phase II study is underway in mBC. We have revised our rNPV to reflect Synta’s effectively exclusive focus on ganetespib and now indicate a valuation of $791m or $11.48/share (basic) or $11.00/share (fully diluted).
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »